The company was founded in 2009 in China. It is an industry-leading high-tech biological products company with the mission of providing solutions for the prevention and treatment of infectious diseases worldwide, focusing on the R&D, production and commercialization of innovative, high-quality, and accessible human vaccines. Cansino Biotech's mission has always been to “provide the world with innovative, high-quality, and accessible vaccines” to achieve the corporate vision of “endless innovation, a world free of diseases”. The company is an innovative vaccine enterprise dedicated to the development, production and commercialization of innovative vaccines that meet Chinese and international standards. The marketed products and product pipeline cover the prevention of meningitis, pneumonia, tuberculosis, COVID-19, Ebola virus disease, shingles, tuberculosis, and many other vaccine varieties with high clinical demand. The main products are MCV4, MCV2, AD5-nCoV, inhaled AD5-nCoV and xBB.1.5 variant vaccines, AD5-eBoV, etc. Corporate honors: National High-tech Enterprise, Tianjin Key Laboratory for Respiratory Bacterial Recombination and Combined Vaccine Enterprises, Nankai University Talent Training Cooperation and Development Base, Tianjin Model Group, etc.
相关临床试验
47
13 进行中
药物批准
8
批准总数
监管机构
1
监管机构数
成立时间
2009
进行中（未招募）
9
19.1%
已完成
25
53.2%
尚未招募
4
8.5%
招募中
4
8.5%
终止
1
2.1%
Unknown
2
4.3%
撤回
2
4.3%
- CanSino Biologics reported approximately RMB550 million in revenue for the first half of 2026, up 43.8% year-on-year, with net loss attributable to shareholders narrowing significantly. - Overseas revenue reached RMB150 million, driven by expansion of mature products and new partnership models involving technology collaboration and local industrialization. - The company's Tripecia three-component DTP vaccine received NDA approval in April 2026, while its 24-valent pneumococcal conjugate vaccine entered Phase I/II trials in May 2026. - CanSinoBIO is advancing mRNA therapeutic programs for glioblastoma, rhabdomyosarcoma and cervical cancer, including a strategic collaboration with deepGeneAI on personalized cancer vaccines.
- CanSino Biologics' New Drug Application for its Td5cp Adolescent and Adult combined vaccine was formally accepted by China's NMPA on August 16, 2026. - The five-component booster vaccine targets people aged six years and above and was granted Priority Review status in May 2026. - Reported pertussis cases in China exceeded 470,000 in 2024, an approximately 12-fold increase from 2023, underscoring the need for adolescent and adult booster immunization. - If approved, the product will complement CanSinoBIO's recently approved three-component DTaP vaccine Tripecia (DT3cP Infant), strengthening its pertussis-containing portfolio across age groups.
- CanSino Biologics' ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (Menhycia®) received drug registration approval from Argentina's ANMAT on June 25, 2026. - Argentina's meningococcal vaccine market, valued at USD 43.8 million in 2025, is projected to reach USD 74.6 million by 2033, representing a CAGR of 6.3%. - Menhycia® is the first quadrivalent meningococcal conjugate vaccine approved in China, offering protection against serogroups A, C, Y, and W135 with stronger immune responses and longer-lasting protection. - The approval aligns with the WHO's Defeating Meningitis by 2030 roadmap, which targets a 50% reduction in vaccine-preventable bacterial meningitis cases and a 70% reduction in deaths by 2030.
- CanSino Biologics has launched iPneucia®, a 13-valent pneumococcal conjugate vaccine specifically optimized for China's local pneumococcal epidemiology to protect Chinese children. - The vaccine targets four high-burden serotypes (19F, 19A, 7F, and 3) that account for over 60% of pneumococcal cases in Chinese children, with clinical data showing significantly higher antibody concentrations against these serotypes. - iPneucia® features innovative dual-carrier conjugate technology using CRM197 and tetanus toxoid proteins, avoiding immune interference and enhancing safety by eliminating formaldehyde detoxification requirements.
- CanSino Biologics has commenced a Phase I/II clinical trial in Indonesia for its Recombinant Poliomyelitis Vaccine (CS-2036). - The CS-2036 vaccine utilizes a non-infectious polio VLP, potentially offering enhanced safety and immunogenicity. - This trial aims to assess the safety and immunogenicity of CS-2036 in infants and toddlers within specific age groups. - The WHO recommends non-infectious polio VLP-based vaccines as a preferred option post-polio eradication.
• CanSino Biologics Inc. (CanSinoBIO) has received approval from China's medical products regulator to begin clinical trials for its mRNA COVID-19 vaccine candidate. • Pre-clinical studies suggest the CanSinoBIO mRNA vaccine elicits high levels of neutralizing antibodies against multiple variants, including Omicron. • China, with approximately 88% of its population vaccinated, is advancing domestically developed mRNA vaccine candidates, as foreign-made mRNA vaccines are yet to be approved.
